K2 Principal Fund’s Biogen BIIB Stock Holding History

K2 Principal Fund’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-3,600	Closed	-$977K	–	329
2017 Q2	$977K	Sell	3,600 -800	-18%	-$212K	0.06%	213
2017 Q1	$1.2M	Buy	4,400 +2,000	+83%	+$565K	0.1%	173
2016 Q4	$681K	Buy	+2,400	New	+$711K	0.06%	188

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

K2 Principal Fund's BIIB Position: Q3 2017 in Review

K2 Principal Fund sold out of Biogen (BIIB) in Q3 2017, closing a stake of 3,600 shares — an estimated $977K sold.

K2 Principal Fund first reported a position in BIIB in Q4 2016 and held it in 3 quarters. The position peaked at $1.2M in Q1 2017. 1,015 funds tracked by Wall St. Rank hold BIIB as of Q3 2017.

K2 Principal Fund reported no remaining Biogen position as of Q3 2017 after selling out during the quarter.
K2 Principal Fund sold 3,600 Biogen shares in Q3 2017, an estimated $977K.
K2 Principal Fund first reported a position in Biogen in Q4 2016 and held it in 3 quarters.
K2 Principal Fund's Biogen position peaked at $1.2M in Q1 2017.
1,015 funds tracked by Wall St. Rank held Biogen as of Q3 2017.

Based on K2 Principal Fund's 13F filing for Q3 2017, filed 9 Nov 2017.